SEGURA-VELAZQUEZ R, Cervantes J, Acosta E, Sanchez. Influenza vaccine: Development of a novel intranasal and subcutaneous recombinant adjuvant. Vaccine. 2013 Jun 4
The synthetic peptide GK-1, derived from Taenia crassiceps, enhances the protection induced by human influenza vaccine in both young and aged mice. Herein, the adjuvant properties of GK-1 fused to the pVIII protein of a heat-inactivated phagemid vector (FGK1) when co-administered with the influenza vaccine were assessed, to evaluate its feasibility as a low-cost adjuvant. In mice, FGK1 significantly increased the expected IgG and IgA anti-influenza antibody levels both in sera and in bronchoalveolar fluids when intranasally or subcutaneously co-administered with influenza vaccine. Single-dose pig co-immunization with FGK1 and influenza vaccine induced serum levels of IgG anti-influenza antibodies similar to those elicited by a two-dose immunization with the influenza vaccine alone. Preclinical evaluation of FGK1 with the influenza vaccine is currently in progress, in order to recommend its use for veterinary purposes.
See Also:
Latest articles in those days:
- Mapping Genetic Markers Associated with Antigenicity and Host Range in H9N2 Influenza A Viruses Infecting Poultry in Pakistan 4 hours ago
- Wastewater-based surveillance is an efficient monitoring tool for tracking influenza A in the community 4 hours ago
- Iceland: an underestimated hub for the spread of high-pathogenicity avian influenza viruses in the North Atlantic 4 hours ago
- Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Dairy Farm Worker 18 hours ago
- [preprint] Emergence and interstate spread of highly pathogenic avian influenza A(H5N1) in dairy cattle 2 days ago
[Go Top] [Close Window]